Asian Currencies Steady as Markets Await U.S. Inflation Data 
Trump Media Says Truth API Draws 10+ Customers as Conflict Concerns Grow 
Anthropic Signs $9.1B AI Data Center Deal With Riot Platforms 
Japan Executives Warn Weak Yen and Currency Volatility Threaten Economy 
Natura Q2 Profit Plunges 92% as Financial Expenses Weigh on Earnings 
US Tightens Ebola Controls as Congo Outbreak Sparks Global Concern 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
CDC Expands Ebola Screening Efforts at U.S. Entry Points Amid Congo and Uganda Outbreak 
Iran-Oman Near Strait of Hormuz Deal as Shipping Tensions Persist 
Takeda Hit With $885M Verdict Over Amitiza Generic Drug Delay Scheme 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Japan Posts First Current Account Deficit in 17 Months as Dividend Payments Surge 
Gold Prices Rise as Fed Rate Hike Bets Ease 
Oil Prices Rise as Hormuz Reopening Remains Uncertain 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
China Inflation Cools in July as CPI Misses Forecast, PPI Deflation Eases 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
Novavax raised doubts about the feasibility of continuing its business after struggles in rolling out its coronavirus jab although it has enough money to fund operations.
The COVID-19 vaccine maker, which described the situation as "subject to significant uncertainty," also announced plans to cut spending
On Tuesday, the company reported a loss of $182 million in the fourth quarter, after posting weaker sales than expected at $357 million.
Consequently, Novavax shares plummeted 25 percent in extended trading.
Novavax is currently gearing up for a fall vaccination campaign and said it plans to focus on delivering an updated COVID-19 vaccine.
The Maryland-based Novavax was an early frontrunner in the global vaccine race but fell behind after being hit by manufacturing and regulatory delays.
The company faced delays in regulatory submissions for its jab, which was only authorized in the US in July last year.
Before that, it received authorization from the European Union, United Kingdom, Canada, and Australia.
